Bocidelpar + Placebo
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
Conditions
Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
Trial Timeline
Jun 14, 2021 → Dec 16, 2022
NCT ID
NCT04855201About Bocidelpar + Placebo
Bocidelpar + Placebo is a phase 1 stage product being developed by Astellas Pharma for Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction. The current trial status is terminated. This product is registered under clinical trial identifier NCT04855201. Target conditions include Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction.
What happened to similar drugs?
7 of 16 similar drugs in Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction were approved
Approved (7) Terminated (3) Active (7)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04855201 | Phase 1 | Terminated |
| NCT04641962 | Phase 2 | Terminated |
| NCT04184882 | Phase 1 | Terminated |
Competing Products
20 competing products in Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction